retatrutide phase 3 results Lilly orforglipron oral GLP-1 weight loss trial Looking forward to when #retatrutide's
Description
Semaglutide GLP-1 is not intended for use in individuals with a BMI below 27 kg/m, as its safety and effectiveness in this population have not been established
Diabetes Care 30 , 15441548 (2007)
Very few telehealth outfits employ MDs to that end
It breaks my heart when I see patients who are doing great on these medications but have to stop because of the cost
Patients today have more effective weight-loss options than ever before, so this is a logical extension of our work, she said
